
    
      This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream 0.05%
      or ARQ-151 cream 0.15% or vehicle is applied QD x 4 weeks to adolescent and adult subjects
      with atopic dermatitis. A subset of subjects will have serial PK testing, which will include
      the first few adolescents and adults enrolled in the study.
    
  